
|Articles|March 19, 2016
Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL
Author(s)Silas Inman
A multitude of PI3K and BTK inhibitors are currently in development that offer distinct advantages over existing treatments for patients with relapsed chronic lymphocytic leukemia.
Advertisement
Susan M. O’Brien, MD
With the onslaught of new PI3K and BTK inhibitors currently in development for patients with relapsed chronic lymphocytic leukemia (CLL), it is challenging to know which therapies are truly “next-generationâ€
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5



































